Betty Hsiao1, Liana Fraenkel1,2. 1. Yale University School of Medicine, New Haven. 2. VA Connecticut Healthcare System, West Haven, Connecticut, USA.
Abstract
PURPOSE OF REVIEW: To provide an overview of recent articles discussing patient preferences for rheumatoid arthritis (RA) treatment. RECENT FINDINGS: Recent studies examined patient preferences for RA treatment in several populations, finding that most participants were willing to accept certain risks of adverse effects to gain potential benefits. Perspectives regarding cannabis were studied, with patients describing medical marijuana as an alternative therapy to be used with prescription medications or as means of tapering off these medications. Treatment preferences for different RA therapies were explored using a conjoint analysis survey and five distinct preference phenotypes emerged, with members of the largest group most concerned with the cost of medications. Other discrete choice studies demonstrated route of administration as an important attribute influencing treatment preferences, with patients expressing preference for various modes in different studies. Patient preferences for route of administration have demonstrated preference for newer autoinjectors over prefilled syringes as well as currently marketed autoinjectors. Incorporating patient preferences in clinical practice recommendations was described in the development of the 2015 American College of Rheumatology (ACR) RA treatment guidelines as well as the 2017 ACR/American Association of Hip and Knee Surgeons guidelines for perioperative management of antirheumatic medications. In addition, other studies explored preferences with regard to predictive testing, medication intensification and tapering, treatment goals, and psychological support. SUMMARY: Our review of recent studies show variability in patient preferences for RA treatment, highlighting the importance of incorporating patient input into the treatment approach.
PURPOSE OF REVIEW: To provide an overview of recent articles discussing patient preferences for rheumatoid arthritis (RA) treatment. RECENT FINDINGS: Recent studies examined patient preferences for RA treatment in several populations, finding that most participants were willing to accept certain risks of adverse effects to gain potential benefits. Perspectives regarding cannabis were studied, with patients describing medical marijuana as an alternative therapy to be used with prescription medications or as means of tapering off these medications. Treatment preferences for different RA therapies were explored using a conjoint analysis survey and five distinct preference phenotypes emerged, with members of the largest group most concerned with the cost of medications. Other discrete choice studies demonstrated route of administration as an important attribute influencing treatment preferences, with patients expressing preference for various modes in different studies. Patient preferences for route of administration have demonstrated preference for newer autoinjectors over prefilled syringes as well as currently marketed autoinjectors. Incorporating patient preferences in clinical practice recommendations was described in the development of the 2015 American College of Rheumatology (ACR) RA treatment guidelines as well as the 2017 ACR/American Association of Hip and Knee Surgeons guidelines for perioperative management of antirheumatic medications. In addition, other studies explored preferences with regard to predictive testing, medication intensification and tapering, treatment goals, and psychological support. SUMMARY: Our review of recent studies show variability in patient preferences for RA treatment, highlighting the importance of incorporating patient input into the treatment approach.
Authors: Glen S Hazlewood; Claire Bombardier; George Tomlinson; Carter Thorne; Vivian P Bykerk; Andrew Thompson; Diane Tin; Deborah A Marshall Journal: Rheumatology (Oxford) Date: 2016-07-31 Impact factor: 7.580
Authors: Emma Dures; Celia Almeida; Judy Caesley; Alice Peterson; Nicholas Ambler; Marianne Morris; Jon Pollock; Sarah Hewlett Journal: Ann Rheum Dis Date: 2014-09-26 Impact factor: 19.103
Authors: David H Collier; Bojena Bitman; Andrew Coles; Lyrica Liu; Sandeep Kumar; Clinton Judd Journal: Postgrad Med Date: 2016-11-09 Impact factor: 3.840
Authors: Samar Al Emadi; Mohammed Hammoudeh; Mohamed Mounir; Ruediger B Mueller; Alvin F Wells; Housam Aldeen Sarakbi Journal: J Int Med Res Date: 2017-03-07 Impact factor: 1.671
Authors: Karin Schölin Bywall; Bente Appel Esbensen; Marta Lason; Marie Heidenvall; Inger Erlandsson; Jennifer Viberg Johansson Journal: Clin Rheumatol Date: 2021-10-15 Impact factor: 2.980